Participants in this research study have sarcoma that has spread or recurred. The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called MLN8237 has on participants and their sarcoma.
MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. This study is approved and sponsored by the National Cancer Institute (NCI). An investigational drug is a medication that has not been approved for use by the U.S. Food and Drug Administration (FDA). The drug is only available in a clinical trial.
Approximately 15 people will take part in this study conducted by investigators at the University of Iowa. Up to 135 subjects will take part in this study at serveral cancer centers nationwide. This includes up to about 30 subjects at Memorial Sloan-Kettering Cancer Center.